TSE:4503Pharmaceuticals
How Investors Are Reacting To Astellas Pharma (TSE:4503) XOSPATA Frontline AML Trial Missing Survival Goal
Astellas Pharma and the HOVON Foundation reported that the Phase 3 HOVON 156/AMLSG 28-18/PASHA trial of XOSPATA (gilteritinib) in newly diagnosed FLT3-mutated acute myeloid leukemia did not meet its primary endpoint of overall survival at the primary analysis, with overall survival and safety broadly similar to midostaurin-based treatment.
Although Astellas expects only a minor impact on financial results for the fiscal year ending March 31, 2026, the outcome underscores how clinical...